Bayer Schering Pharma outlines haemophilia research commitment

Bayer Schering Pharma has underlined its continuing commitment to advancing haemophilia treatment standards at an international conference.

The pharmaceutical company addressed more than 400 industry experts at the Bayer Schering Pharma Haematology Conference 2010 in Athens to highlight the progress it is making with the research and development of new drugs for the condition.

Dr Georg Lemm, head of clinical development for the haematology product line of Bayer Schering Pharma, stated that the company's objectives are to deliver a successor to its Factor VIII product Kogenate Bayer and to create drugs which can treat bleeding and optimise bypass therapy.

It highlighted the rFVIIa compound BAY 86-6150 as showing promise in this respect, with a pivotal phase II/III study of the drug due to commence soon.

Dr Lemm said: "We aim to expand scientific knowledge and clinical skills that may improve the lives of patients living with haemophilia."

Earlier this month, Bayer Schering Pharma announced that it has received European Commission clearance to launch Levitra, its new tablet-based treatment for erectile dysfunction.